European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A ...Middle East

STOCKHOLM, June 19, 2024 /PRNewswire/ -- Sobi® today announced the European Commission has granted Marketing Authorisation for ALTUVOCT™ (efanesoctocog alfa), for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. ALTUVOCT is a high-sustained factor...

Hence then, the article about european commission grants sobi marketing authorisation for altuvoct for treatment of haemophilia a was published today ( Wednesday 19/06/2024 - 09:32 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A )

Also on site :

• Heat Warning Issued as 450,000 Told Stay Inside for 60 Hours in California
• UCSD, San Diego State part of widespread attack on Canvas education platform
• Europeans want to break free from US – survey